Our results highlight the clinical potential of molecular-based tumor targeting nanoparticles as gene therapy vehicles as well as the therapeutic benefit of TUSC2-erlotinib combination in wild type EGFR NSCLC. The gene discussed is EGFR; the disease is neoplasm.